IP Verse

Treatment Of Cancer Using Chimeric Antigen Receptor

Patent No. EP3119423 (titled "Treatment Of Cancer Using Chimeric Antigen Receptor") was filed by Novartis on Mar 13, 2015. The application was issued on Dec 14, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MARGARET DIXONSep 14, 2023MEWBURN ELLIS
PATENT BOUTIQUESep 14, 2023-
MURGITROYDSep 13, 2023-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3119423

NOVARTIS
Application Number
EP15712503A
Filing Date
Mar 13, 2015
Status
Granted And Under Opposition
Nov 11, 2022
Publication Date
Dec 14, 2022
External Links
Slate, Register , Google Patents